Managing HS Today: What’s New, What Works, and What’s Next in Hidradenitis Suppurativa: An Online Activity

Treating patients with hidradenitis suppurativa (HS) and wondering how to navigate some of those clinical practice challenges? In this combination of highlights from the HS satellite symposia at the 2026 Winter Clinical Hawaii and Miami Dermatology Conferences, our expert faculty will guide you through the nuances of patient-centered, evidence-based HS care.  

“I think the point here is that (patients with HS) could be biologic candidates. That can really impact a patient's quality of life, no matter if there's one abscess, a few nodules, a few scars – you really need to think about biologic treatment. And of course, in a perfect world, we would have accessed these patients earlier and prevented a lot of these scars in the first place.” – Dr. Andrea Murina 

Managing HS Today: What’s New, What Works, and What’s Next in Hidradenitis Suppurativa: An Online Activity 

This activity is supported by educational grants from Incyte, Novartis Pharmaceuticals Corporation, and UCB Inc.